Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01710839 · ClinicalTrials.gov registry record · Phase 4
Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion
A Phase 4 study, sponsored by Charles C Wykoff, PhD, MD.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT01710839 is a Phase 4 study that has completed, run by Charles C Wykoff, PhD, MD. The registered enrollment target is 30 participants.
The verdict
NCT01710839, a Phase 4 study, has completed, sponsored by Charles C Wykoff, PhD, MD.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
To see if Lucentis 0.5mg combined with Targeted Pan Retinal photocoagulation will decrease the total number of intravitreal injections in a year for ischemic central retinal vein occlusion, hemi-retinal vein occlusions and branch retinal vein occlusions compared to standard of care
Interventions
- PROCEDURE Targeted Pan Retinal Photocoagulation
- DRUG 0.5mg Ranibizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2012-10 |
| Est. Completion | 2015-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01710839
The ClinicalTrials.gov registry entry for NCT01710839 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Charles C Wykoff, PhD, MD, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Targeted Pan Retinal Photocoagulation is the first listed.
NCT01710839 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01710839 about?
NCT01710839 is a clinical study titled "Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion". To see if Lucentis 0.5mg combined with Targeted Pan Retinal photocoagulation will decrease the total number of intravitreal injections in a year for ischemic central retinal vein occlusion, hemi-retinal vein occlusions and branch retinal vein occlusions compared to standard of care
What is the current status of trial NCT01710839?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2012-10. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01710839?
The interventions under investigation include: Targeted Pan Retinal Photocoagulation (PROCEDURE), 0.5mg Ranibizumab (DRUG).
Who is sponsoring clinical trial NCT01710839?
This trial is sponsored by Charles C Wykoff, PhD, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.